Xortx TherapeuticsXRTX
13F holders, Q3 2024 (September 30)7holders +2
3new positions
1sold out
$1.67avg. 13F price*
At the end of Q3 2024, 7 institutions reported holding Xortx Therapeutics Inc. (XRTX) in their 13F filings, up 2 from Q2 2024. 3 opened new positions and 1 sold out. The largest holders were UBS Group AG ($31K), National Bank of Canada ($6K) and Osaic Holdings, Inc. ($2K).
- Company
- Xortx Therapeutics Inc.
- CUSIP
- 98420Q306
- Latest filing quarter
- Q1 2026
History
Number of 13F holders
Total Exit/New Position Q2 2024 → Q3 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 3 | $37K |
| Exits | 1 | $23K |
All 13F filers, Q2 2024 → Q3 2024: 22,304 shares bought and 12,887 shares sold, net +9,417 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 7 holders
| UBS Group AG | 0.00% | New | 18,780 | $31K |
| National Bank of Canada | 0.00% | New | 3,440 | $6K |
| Osaic Holdings, Inc. | 0.00% | No change | 1,153 | $2K |
| JPMorgan Chase & Co. | 0.00% | No change | 254 | $1K |
| Royal Bank of Canada | 0.00% | Reduce -45.2% | 672 | $1K |
| Clearstead Advisors, LLC | 0.00% | No change | 277 | $455 |
| Tower Research Capital LLC (TRC) | 0.00% | New | 84 | $138 |
"% of holder's portfolio" is XRTX's weight in each manager's 13F, not the share of Xortx Therapeutics Inc. the manager owns.